News

ORMP

​Here's Why Oramed Pharmaceuticals Is a Stock to Watch Right Now

Mark Collins | Equities.com |

Here's a look at where Oramed fits into the diabetes landscape.


Oramed Receives Additional $4 Million Milestone Payment From HTIT

Press Releases | Equities.com |

Totaling $25.5 M in payments from HTIT received to date


Oramed Announces $6.5 Million Milestone Payment from HTIT

Press Releases | Equities.com |

Payment comes in wake of positive topline phase IIB results


Oramed Completes Phase IIb Oral Insulin Study

Press Releases | Equities.com |

Oramed Pharmaceuticals announced today that all follow-up visits in the Company's Phase IIb study of its oral insulin capsule, ORMD-0801, have been completed.


4 Emerging Growth Biotech Names for the Next Generation

The Life Sciences Report | Equities.com |

There's been a significant rotation out of speculative healthcare names. Does this mean opportunity?



Discover: Trending Events

United Nations
Blockchain for Europe
Humanity 2.0
World Economic Forum